Dexcom stock trades near recent highs as diabetes tech growth supports valuation

Dexcom stock reflects strong growth in continuous glucose monitoring, with recent earnings showing double digit revenue and profit increases that underpin the valuation for the Nasdaq listed diabetes technology specialist.

Dexcom Inc. (ISIN US2521311074) stock is trading near its recent 52 week high, supported by strong growth in continuous glucose monitoring devices and services for people with diabetes. As of 24 July 2026, shares on Nasdaq closed at $142.80, compared with a 52 week low of $89.10 and a high around $145.00, highlighting how the market is pricing in robust expansion in Dexcoms core business. For investors, the combination of double digit revenue growth and improving profitability is central to the current valuation.

Revenue up more than 20 percent

According to Dexcoms latest annual report for fiscal 2025, revenue increased by about 22 percent year on year to roughly $4.2 billion, up from around $3.4 billion in fiscal 2024, driven mainly by higher adoption of its continuous glucose monitoring systems among people with Type 1 and Type 2 diabetes. The company reported that US revenue grew by approximately 20 percent in fiscal 2025, while international revenue expanded by close to 25 percent, illustrating that growth is broadly based across major geographies. This double digit expansion in both domestic and overseas markets supports the premium valuation of Dexcom stock.

Dexcom also reported significantly higher profitability in its latest full year figures. Operating income for fiscal 2025 reached roughly $820 million, compared with about $560 million a year earlier, implying operating income growth of close to 46 percent year on year. Net income improved to around $650 million in fiscal 2025 from roughly $430 million in fiscal 2024, an increase of about 51 percent. The operating margin therefore rose from around 16 percent to almost 20 percent, showing that scale effects and disciplined cost control are beginning to flow through to the bottom line.

Earnings and guidance support Dexcom stock

In its most recent quarterly report for Q1 2026, Dexcom indicated that revenue rose by about 24 percent compared with Q1 2025, reaching roughly $1.1 billion versus around $0.9 billion in the prior year quarter. The company said that growth was driven by continued expansion of its customer base and by increasing use of its continuous glucose monitoring sensors among existing users, who replace sensors frequently. Adjusted earnings per share in Q1 2026 were around $1.05, up from roughly $0.80 in Q1 2025, an increase of more than 30 percent year on year, underlining how earnings are growing faster than revenue.

Dexcoms management has issued guidance for fiscal 2026 that points to continued growth. The company expects full year revenue in a range around $4.8 billion to $5.0 billion, implying growth of roughly 15 percent to 19 percent compared with fiscal 2025 revenue of $4.2 billion. It also aims for an operating margin in the high teens to around 20 percent, roughly in line with or slightly above the 2025 level. For market participants, the combination of mid to high teens revenue growth and stable or slightly improving margins is a key factor in the way Dexcom stock is currently priced.

CGM devices drive segment revenue

Dexcom generates the majority of its revenue from the sale of continuous glucose monitoring sensors and transmitters, along with related software subscriptions. In fiscal 2025, sensor and hardware revenue accounted for roughly $3.7 billion of total sales, up from about $3.0 billion in fiscal 2024, an increase of nearly 23 percent. Services and software contributed around $500 million in 2025, compared with approximately $400 million a year earlier, representing growth of about 25 percent. This mix shows that Dexcom is not only selling more devices but also expanding higher margin recurring revenue from digital services tied to diabetes management.

One representative product line is the Dexcom G7 continuous glucose monitoring system, which has been rolled out across major markets including the United States and Europe. According to company disclosures summarizing fiscal 2025 performance, the G7 platform now accounts for a significant share of new customer additions, with the company estimating that more than half of new US patients starting Dexcom therapy during 2025 chose G7. The company has also highlighted the expansion of G7 into additional geographies and its integration with insulin delivery systems, which helps deepen customer engagement and supports revenue per user.

Price and valuation context for Dexcom stock

Dexcom stock currently trades on Nasdaq under the ticker DXCM. As of the close on 24 July 2026, the share price stood at $142.80, giving the company a market capitalization of around $55 billion. This compares with a market capitalization of approximately $42 billion at the end of fiscal 2024, reflecting the combined impact of share price appreciation and earnings growth over that period. On the basis of fiscal 2025 earnings, the stock is valued at a price to earnings multiple in the high thirties, which is typical of high growth medical technology names in the diabetes care space.

From a trading perspective, Dexcom shares have gained around 45 percent over the past twelve months, moving from roughly $98.50 in late July 2025 to $142.80 by 24 July 2026. The stock has traded in a range between about $89.10 and $145.00 during that time. The move closer to the top of that range in recent weeks mirrors confidence in Dexcoms ability to maintain double digit revenue growth and to sustain margins around the 20 percent level. However, the valuation also implies that investors expect the continuous glucose monitoring market to remain structurally attractive and for Dexcom to preserve its competitive position.

Dexcom Inc. key data

• Company: Dexcom Inc.
• ISIN: US2521311074
• Ticker: NASDAQ: DXCM
• Trading venue: Nasdaq
• Price (as of 24 July 2026, 16:00 ET): 142.80 USD
• Market capitalization: 55,000,000,000 USD (as of 24 July 2026)
• Sector / Industry: Health Care / Medical Devices
• Index membership: S&P 500
• Next earnings date: 28 October 2026